



Vaccine Development for Viral Infection

Guest Editors:

Dr. Morgane Solis

Virology Laboratory, Strasbourg
University Hospitals, 67000
Strasbourg, France

Dr. Minhui Guan

MU Center for Influenza and
Emerging Infectious Diseases,
University of Missouri, Columbia,
MO 65211, USA

Deadline for manuscript
submissions:
closed (12 July 2023)

Message from the Guest Editors

The SARS-CoV-2 pandemic has stimulated vaccine research and accelerated the development of innovative vaccine strategies. These vaccines appear essential to protect against severe forms of COVID-19 and to help to mitigate the global impact of SARS-CoV-2. While some viral diseases have been easily controlled and some eradicated by vaccines, there are still many viruses against which the development of an effective vaccine remains a dream.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: epidemiological, biological, and clinical aspects related to already existing vaccines as well as advances in the development of new vaccines against viral infections, especially against the ones that currently do not have any vaccine available, e.g., other respiratory viruses such as RSV, viruses of the immunocompromised such as Polyomaviruses, or other global pandemics such as HIV. Vaccines against emerging viruses and current vaccines improvements are also welcomed themes.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com